Tue.Jan 16, 2024

article thumbnail

FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia

Bio Pharma Dive

The agency’s decision to expand use of Casgey, which won a landmark OK for sickle cell disease in December, comes more than two months ahead of schedule.

Medicine 317
article thumbnail

XNK Therapeutics’ Evencaleucel gains EMA recommendation

Pharmaceutical Technology

XNK Therapeutics has received scientific recommendation from the EMA's Committee for Advanced Therapies (CAT) for its product evencaleucel.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Simplifying speaker engagement in Pharma: A holistic approach

Bio Pharma Dive

Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.

279
279
article thumbnail

Rabies Is a Deadly, Unpredictable Threat. Here’s How to Protect Yourself.

AuroBlog - Aurous Healthcare Clinical Trials blog

A feral kitten in Omaha, Nebraska, tested positive for rabies in November 2023. It died of the raccoon variant of the virus, which is typically found only in the Appalachian Mountains.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Women’s health companies, battling under-investment in research, see growing opportunity

Bio Pharma Dive

While investment remains lower than in other areas of drug R&D, executives and VCs speak of growing momentum for a field that’s been overlooked in the past.

Research 219
article thumbnail

Parexel, JFCR ink agreement to accelerate access to oncology clinical trials in Japan

AuroBlog - Aurous Healthcare Clinical Trials blog

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, has announced a strategic alliance to accelerate access to oncology clinical trials in Japan.

More Trending

article thumbnail

IRA lawsuits will test US’ ability to regulate social pricing in pharma

Pharmaceutical Technology

As the deadline nears for the government to reveal its proposed prices, pharmaceutical companies are continuing to fight regulation.

article thumbnail

Allakos to lay off half of staff, scrap drug after study setback

Bio Pharma Dive

The restructuring adds to a wave of industry layoffs and makes the Californian biotech at least third this year to reduce its workforce by at least 50%.

Drugs 182
article thumbnail

Roche’s Tecentriq SC receives EC approval for cancer treatment

Pharmaceutical Technology

Roche has received marketing authorisation from the EC for Tecentriq SC for subcutaneous administration to treat cancers.

Marketing 162
article thumbnail

January 16, 2024: Ethics Consultation Documents Now Available for AIM-CP and MOMs Chat & Care Study

Rethinking Clinical Trials

Ethics and regulatory onboarding documentation for 2 of the NIH Pragmatic Trials Collaboratory's newest trials is now available. The documents include meeting minutes and supplementary materials summarizing recent discussions of ethics and regulatory issues associated with the AIM-CP trial and the MOMs Chat & Care Study. The consultations took place by video conference and included representation from the studies' principal investigators, members of the NIH Collaboratory's Ethics and Regulat

Trials 147
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Allakos cuts employee count by half after two Phase II failures 

Pharmaceutical Technology

Allakos’ stock price has plummeted following the announcement of two Phase II studies failing to meet their primary endpoints.

130
130
article thumbnail

Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Fierce Pharma

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.

article thumbnail

Roche exec says more pull incentives are needed to tackle AMR

Pharmaceutical Technology

Antimicrobial resistance is the third leading cause of death globally, with no major advances in the field in the past 50 years.

130
130
article thumbnail

Does CNS Drug Development Need to Evolve to Include Objective, Longitudinal and Broad-Spectrum Data?

XTalks

To date, the lack of objective longitudinal measures in central nervous system (CNS) clinical studies has resulted in less than 6 percent of drugs in this space making it to market. Many of the validated cognitive assessments today are paper based, introducing the potential for bias and limiting ethnic and geographic diversity in clinical studies. Additionally, blood biomarkers only provide a snapshot in time and do not provide insight into cognitive function.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

AbbVie-backed Disco emerges from stealth with $21.8m

Pharmaceutical Technology

Disco has built a protein mapping platform for cancer cell surfaces, to unlock targets for the antibody-based therapy market.

Protein 130
article thumbnail

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Bioengineer

The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms.

Genomics 119
article thumbnail

BioSenic and Phebra switch up terms of licensing agreement

Pharmaceutical Technology

The updated binding term sheet for an oral arsenic trioxide therapy sees Phebra take on more duties and BioSenic given royalties.

Licensing 130
article thumbnail

GSK pumps £200M+ into UK manufacturing network to bolster commercial ambitions, API supply

Fierce Pharma

As British pharma giant AstraZeneca looks abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next t | As other British drugmakers like AstraZeneca look abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next two years.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

UK MHRA announces new data flagging potential valproate risks  

Pharmaceutical Technology

The MHRA said that males planning a family in the next year should consult their healthcare professional before valproate use.

130
130
article thumbnail

Takeda picks up 2nd FDA-approved indication for immune globulin treatment HyQvia

Fierce Pharma

The FDA has approved Takeda's HyQvia as a maintenance therapy for CIDP. It is the second indication for HyQvia, which was first endorsed in 2014.

article thumbnail

Santhera introduces AGAMREE for DMD treatment in Germany

Pharmaceutical Technology

Santhera Pharmaceuticals has announced the introduction of AGAMREE to treat Duchenne muscular dystrophy (DMD) patients in Germany.

130
130
article thumbnail

DISCO dances out of the shadows with €20m for ‘surfaceome’

pharmaphorum

DISCO Pharma has emerged from stealth with €20m in seed financing that will be used to advance its surfaceome cancer target-hunting platform

115
115
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

How building a global data core delivers commercial agility for the future

Pharmaceutical Technology

Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing data across an organization can help biopharmas deliver a superior customer experience, scale globally, and become more agile in their business.

130
130
article thumbnail

Transformative trends with real-world data from early access programmes

pharmaphorum

In addition to bringing treatment and hope to patients without alternatives, early access programmes provide further information on a product’s safety and efficacy data in real-world conditions.

115
115
article thumbnail

FDA grants orphan drug status to Neuraptive Therapeutics’ NTX-001

Pharmaceutical Technology

The US FDA has granted orphan drug designation to Neuraptive Therapeutics’ NTX-001, a treatment kit for peripheral nerve injury repair.

Drugs 130
article thumbnail

An AI Approach to Generate Novel Pharmaceuticals using Patent Data

Drug Patent Watch

A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures… The post An AI Approach to Generate Novel Pharmaceuticals using Patent Data appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

The power of preference: How healthcare providers can build trust with consumers

Pharmaceutical Technology

Patients play their cards close to their chest when it comes to sharing their personal information.

130
130
article thumbnail

Merck's Keytruda again bags industry-first cervical cancer nod—with limitation

Fierce Pharma

After crowning Keytruda as the first immunotherapy for advanced cervical cancer back in 2021, the FDA has awarded the drug another industry-first designation in an earlier stage of the tumor type. | After crowning Keytruda as the first immunotherapy for advanced cervical cancer back in 2021, the FDA has awarded the drug another industry-first designation in an earlier stage of the tumor type.

Drugs 111
article thumbnail

Roche bags EU okay for subcutaneous Tecentriq

pharmaphorum

Roche’s Tecentriq has become the first PD-1/PD-L1 inhibitor to be cleared in the EU in a subcutaneous form that will make dosing easier for patients and healthcare providers

111
111
article thumbnail

Aston University receives £10m for membrane institute

Pharma Times

Aston University to create the Aston Institute for Membrane Excellence

111
111
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.